J. Hoeg, E. Schaefer, Carol A Romano
Oct 1, 1984
Citations
0
Influential Citations
23
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9‐mo, double‐blind, randomized, crossover, placebo‐controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safety, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low‐density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high‐density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto‐ or nephrotoxicity. Neomycin treatment in patients with type II hyperlipoproteinemia is an inexpensive and effective means of lowering the concentration of low‐density lipoproteins and is free of significant side effects over a 3‐mo period.